IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis
Completed
Paratek Pharmaceuticals Inc
Phase 2
2018-11-19
The purpose of this study was to evaluate the safety and efficacy of intravenous (iv) or
iv/per oral (po) omadacycline as compared to iv or iv/po levofloxacin in the treatment of
female adults with acute pyelonephritis.
Omadacycline Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis
Completed
Paratek Pharmaceuticals Inc
Phase 1
2020-02-10
This study will determine the tissue penetration of the novel tetracycline antibiotic,
omadacycline (Nuzyra, Paratek Pharmaceuticals, Inc.), into the extracellular, interstitial
fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will
be compared with a group of healthy volunteer control participants.
Omadacycline Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis
Completed
Hartford Hospital
Phase 1
2020-02-10
This study will determine the tissue penetration of the novel tetracycline antibiotic,
omadacycline (Nuzyra, Paratek Pharmaceuticals, Inc.), into the extracellular, interstitial
fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will
be compared with a group of healthy volunteer control participants.
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
Recruiting
Paratek Pharmaceuticals Inc
Phase 3
2021-02-25
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared
to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)
Recruiting
Paratek Pharmaceuticals Inc
Phase 2
2021-10-15
The purpose of this study is to evaluate the efficacy, safety and tolerability of oral
omadacycline as compared to placebo in the treatment of adults with Nontuberculous
Mycobacterial (NTM) pulmonary disease caused by Mycobacterium abscessus complex (MABc)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
